|
Dr. Craig leverages more than 15 years of clinical, oncology, management and drug development experience to direct ChemGenex’s global clinical development strategies and to lead ChemGenex’s clinical development and translational medicine team. Dr. Craig has extensive expertise in building and managing clinical teams focused on product registration, with particular experience in developing therapies for hematologic malignancies such as chronic myeloid leukemia (CML). Most recently, he was Vice President and founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., an oncology and hematology drug development company based in New York. Previously, Dr. Craig held positions of increasing responsibility including Vice President and Medical Director at ArQule Inc., Senior Director at Ilex Oncology Inc., and Medical Advisor at Antisoma plc. Dr. Craig received his medical qualifications from London University, a PhD in molecular medicine at the University of Leeds, and an MBA from the Open Business School, in the United Kingdom. Dr. Craig is a member of the Royal College of Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology. | 